TABLE 1 from A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

NIAID Data Ecosystem2026-05-01 收录

数据链接：

https://figshare.com/articles/dataset/TABLE_1_from_A_Phase_I_II_Clinical_Trial_of_Pembrolizumab_and_Cabozantinib_in_Metastatic_Renal_Cell_Carcinoma/23393629 数据链接链接失效反馈

官方服务：

资源简介：

Baseline characteristics

创建时间：

2023-06-08

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

肾细胞癌治疗

药物经济学

Background:Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of ta

NIAID Data Ecosystem50

Overview of the current literature, comparing studies with patients presenting pT2 and cT2 RCC and treated by nephron sparing surgery (NSS) or radical nephrectomy (RN).

肾细胞癌治疗

骨科手术疗效

Synopsis current literature.

Figshare2018-05-04 更新30

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-Ribose Polymerase inhibitors and low-dose alkylating chemotherapy. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-Ribose Polymerase inhibitors and low-dose alkylating chemotherapy

肾细胞癌治疗

Krebs循环缺陷肿瘤

In this study, we evaluated novel treatment approaches in newly generated models of FH- and SDHB-deficient RCC. CRISPR/Cas9 was used to engineer isogenic Fh1- and Sdhb-deficient murine models of RCC.

NIAID Data Ecosystem20

Supplementary material: Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

网络荟萃分析

肾细胞癌治疗

These are peer-reviewed supplementary materials for the article 'Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-

becaris.figshare.com2024-04-15 更新50

Genome wide expression change by 786-O cells treated with MST1/2 inhibitor XMU-MP-1. Genome wide expression change by 786-O cells treated with MST1/2 inhibitor XMU-MP-1

肾细胞癌治疗

基因表达分析

We aim to the investigate the role of MST1/2 inhibitor XMU-MP-1 in kindy renal clear cell carcinoma (ccRCC) progression. 786-O cells were used as the model. Overall design: The 786-O cells were treate

NIAID Data Ecosystem20

TABLE 1 from A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

资源简介：

相关数据集